Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00873366 · ClinicalTrials.gov registry record
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 92
- Enrollment target
NCT00873366: Clinical Trial study, sponsored by Mayo Clinic.
NCT00873366 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 92 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00873366 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 92 participants
- Enrollment target
Study Summary
RATIONALE: A breath test that measures enzymes may be effective in identifying women in whom tamoxifen may not be effective. PURPOSE: This clinical trial is studying a breath test to see how well it works in women receiving tamoxifen for the prevention or treatment of breast cancer.
Primary Outcome
Participants were classified as having CYP2D6 decreased or non-decreased metabolism based on genotype and the co-prescription of inhibitors of the enzyme system. The specific phenotype, alleles and their associated activity score (AS) assessed were as follows: Ultrarapid metabolism (UM) or AS=2.0 (\*1XN or \*2XN), Extensive metabolism (EM) or AS=1.0 (\*1, \*2, and \*2A), Intermediate metabolism (IM) or AS=0.5 (\*9, \*10, \*17 and \*41), and Poor metabolism (PM) or AS=0.0 (3, \*4, \*5, \*7, \*8
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacogenomic studies
- DRUG tamoxifen citrate
- OTHER high performance liquid chromatography
- DRUG dextromethorphan hydrobromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2009-05 |
| Est. Completion | 2015-09-23 |
Why NCT00873366 stopped before completion
NCT00873366 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 92 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00873366 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00873366 about?
NCT00873366 is a clinical study titled "Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer". RATIONALE: A breath test that measures enzymes may be effective in identifying women in whom tamoxifen may not be effective. PURPOSE: This clinical trial is studying a breath test to see how well it works in women receiving tamoxifen for the prevention or treatment of breast cancer.
What is the current status of trial NCT00873366?
This trial is currently terminated. The enrollment target is 92 participants. The study started on 2009-05. Estimated completion is 2015-09-23.
What interventions are being tested in trial NCT00873366?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacogenomic studies (OTHER), tamoxifen citrate (DRUG), high performance liquid chromatography (OTHER), dextromethorphan hydrobromide (DRUG).
Who is sponsoring clinical trial NCT00873366?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia